Showing 19,841 - 19,860 results of 108,906 for search '(( 5 ((ppm decrease) OR (((a decrease) OR (mean decrease)))) ) OR ( a point decrease ))', query time: 1.72s Refine Results
  1. 19841

    Table_2_EXOSC5 as a Novel Prognostic Marker Promotes Proliferation of Colorectal Cancer via Activating the ERK and AKT Pathways.DOCX by Hongda Pan (6996182)

    Published 2019
    “…<p>Background and Objective: Exosome component 5 (EXOSC5) is a novel cancer-related gene that is aberrantly expressed in various malignances. …”
  2. 19842

    Data_Sheet_1_Niclosamide as a chemical probe for analyzing SARS-CoV-2 modulation of host cell lipid metabolism.zip by Timothy J. Garrett (7418819)

    Published 2023
    “…</p>Methods<p>We used niclosamide (NIC), a poorly soluble anti-helminth drug identified initially for repurposed treatment of COVID-19, which activates the cells’ autophagic and lipophagic processes as a chemical probe to determine if it can modulate the host cell’s total lipid profile that would otherwise be either amplified or reduced during SARS-CoV-2 infection.…”
  3. 19843
  4. 19844

    Table_3_EXOSC5 as a Novel Prognostic Marker Promotes Proliferation of Colorectal Cancer via Activating the ERK and AKT Pathways.XLSX by Hongda Pan (6996182)

    Published 2019
    “…<p>Background and Objective: Exosome component 5 (EXOSC5) is a novel cancer-related gene that is aberrantly expressed in various malignances. …”
  5. 19845
  6. 19846

    Table_3_EXOSC5 as a Novel Prognostic Marker Promotes Proliferation of Colorectal Cancer via Activating the ERK and AKT Pathways.XLSX by Hongda Pan (6996182)

    Published 2019
    “…<p>Background and Objective: Exosome component 5 (EXOSC5) is a novel cancer-related gene that is aberrantly expressed in various malignances. …”
  7. 19847
  8. 19848

    Table_2_EXOSC5 as a Novel Prognostic Marker Promotes Proliferation of Colorectal Cancer via Activating the ERK and AKT Pathways.DOCX by Hongda Pan (6996182)

    Published 2019
    “…<p>Background and Objective: Exosome component 5 (EXOSC5) is a novel cancer-related gene that is aberrantly expressed in various malignances. …”
  9. 19849
  10. 19850

    Image_2_Myricetin, the Main Flavonoid in Syzygium cumini Leaf, Is a Novel Inhibitor of Platelet Thiol Isomerases PDI and ERp5.tiff by Renato Simões Gaspar (8384040)

    Published 2020
    “…Additionally, myricetin is a novel inhibitor of ERp5 and PDI, unveiling a new therapeutic perspective for the treatment of thrombotic disorders.…”
  11. 19851
  12. 19852
  13. 19853

    Image_4_Myricetin, the Main Flavonoid in Syzygium cumini Leaf, Is a Novel Inhibitor of Platelet Thiol Isomerases PDI and ERp5.jpeg by Renato Simões Gaspar (8384040)

    Published 2020
    “…Additionally, myricetin is a novel inhibitor of ERp5 and PDI, unveiling a new therapeutic perspective for the treatment of thrombotic disorders.…”
  14. 19854
  15. 19855
  16. 19856

    Table 5_Does COVID-19 vaccination affect risk perception and adherence to preventive behaviors? A systematic review and meta-analysis.docx by Michele Sorrentino (16538214)

    Published 2025
    “…Potential biases were assessed using the MMAT tool. A meta-analysis calculated pooled effect sizes across subgroups.…”
  17. 19857

    Table_6_Two DNA Methyltransferases for Site-Specific 6mA and 5mC DNA Modification in Xanthomonas euvesicatoria.XLSX by Hye-Jee Park (3594245)

    Published 2021
    “…Xe(XvDMT2) was more tolerant to EtOH than Xe(XvDMT1), which had enhanced tolerance to sorbitol but decreased tolerance to polymyxin B. Using single-molecule real-time sequencing and methylation-sensitive restriction enzymes, we successfully predicted putative motifs methylated by XvDMT1 and XvDMT2, which are previously uncharacterized 6mA and 5mC DNA MTases, respectively. …”
  18. 19858

    Image_1_Myricetin, the Main Flavonoid in Syzygium cumini Leaf, Is a Novel Inhibitor of Platelet Thiol Isomerases PDI and ERp5.tif by Renato Simões Gaspar (8384040)

    Published 2020
    “…Additionally, myricetin is a novel inhibitor of ERp5 and PDI, unveiling a new therapeutic perspective for the treatment of thrombotic disorders.…”
  19. 19859

    Image_5_The harmful intestinal microbial community accumulates during DKD exacerbation and microbiome–metabolome combined validation in a mouse model.tif by Jin Shang (704634)

    Published 2022
    “…Untargeted metabolome–microbiome combined analysis of mouse models helps decipher the pathogenetic mechanism from a metabolic perspective.</p>Results<p>The diversity of the gut microbiome was significantly decreased in DKD patients when compared with that of the non-DKD population and was increased in the patients with more advanced DKD stages. …”
  20. 19860

    Table_3_Two DNA Methyltransferases for Site-Specific 6mA and 5mC DNA Modification in Xanthomonas euvesicatoria.XLSX by Hye-Jee Park (3594245)

    Published 2021
    “…Xe(XvDMT2) was more tolerant to EtOH than Xe(XvDMT1), which had enhanced tolerance to sorbitol but decreased tolerance to polymyxin B. Using single-molecule real-time sequencing and methylation-sensitive restriction enzymes, we successfully predicted putative motifs methylated by XvDMT1 and XvDMT2, which are previously uncharacterized 6mA and 5mC DNA MTases, respectively. …”